Jozien Helleman

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi Molecular profiling of platinum resistant ovarian cancer
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC/Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Int J Cancer 118:1963-71. 2006
  2. ncbi Mismatch repair and treatment resistance in ovarian cancer
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    BMC Cancer 6:201. 2006
  3. ncbi Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC JNI Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Gynecol Oncol 117:170-6. 2010
  4. ncbi Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC, Josephine Nefkens Institute, Rotterdam, The Netherlands
    Breast Cancer Res Treat 116:263-71. 2009
  5. ncbi Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Biol Ther 5:943-9. 2006
  6. ncbi Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC JNI, Rotterdam, The Netherlands
    Int J Biochem Cell Biol 42:25-30. 2010
  7. ncbi Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 14:5555-64. 2008
  8. ncbi Cyclopentenyl cytosine primes SK-N-BE(2)c neuroblastoma cells for cytarabine toxicity
    Jörgen Bierau
    Department of Clinical Chemistry, Emma Children s Hospital, Academic Medical Center, University of Amsterdam, The Netherlands
    Int J Cancer 103:387-92. 2003

Detail Information

Publications8

  1. ncbi Molecular profiling of platinum resistant ovarian cancer
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC/Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Int J Cancer 118:1963-71. 2006
    ..A larger independent multicentre study should further confirm whether this 9-gene set can identify the patients who will not respond to platinum-based chemotherapy and could benefit from other therapies...
  2. ncbi Mismatch repair and treatment resistance in ovarian cancer
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    BMC Cancer 6:201. 2006
    ..The aim of this study is to determine the frequency of mismatch repair (MMR) inactivation in ovarian cancer and its association with resistance to platinum-based chemotherapy...
  3. ncbi Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC JNI Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Gynecol Oncol 117:170-6. 2010
    ..With this exploratory study, we aim to identify overlapping pathways associated with platinum-based chemotherapy resistance mechanisms in ovarian cancer...
  4. ncbi Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC, Josephine Nefkens Institute, Rotterdam, The Netherlands
    Breast Cancer Res Treat 116:263-71. 2009
    ..The aim of this study was to evaluate SIAH2 for its (a) predictive/prognostic value, and (b) functional role in endocrine therapy resistance...
  5. ncbi Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Biol Ther 5:943-9. 2006
    ..In conclusion, we generated an A2780 subline that showed a uniquely stable platinum resistance phenotype, which could theoretically be caused by an impaired inward transporter specific for cis-configurated platinum compounds...
  6. ncbi Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC JNI, Rotterdam, The Netherlands
    Int J Biochem Cell Biol 42:25-30. 2010
    ..A model is presented based on literature linking transforming growth factor beta, extracellular matrix, integrin signalling, epithelial to mesenchymal transition and regulating microRNAs with a (bivalent) role in chemotherapy response...
  7. ncbi Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 14:5555-64. 2008
    ....
  8. ncbi Cyclopentenyl cytosine primes SK-N-BE(2)c neuroblastoma cells for cytarabine toxicity
    Jörgen Bierau
    Department of Clinical Chemistry, Emma Children s Hospital, Academic Medical Center, University of Amsterdam, The Netherlands
    Int J Cancer 103:387-92. 2003
    ..In contrast, AraC alone did not induce caspase-3 activity. Our results demonstrate that low concentrations of CPEC profoundly increase the cytostatic properties of AraC toward SK-N-BE(2)c human neuroblastoma cells...